Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Exceptional extension!
Enjoy this offer
* See conditions under "Our services"

Valuation: Genome & Company

Market Cap 20TCr 13Cr 11Cr 10Cr 9.65Cr 18Cr 1.21TCr 18Cr 123.82Cr 48Cr 592.11Cr 48Cr 47Cr 2.06TCr P/E 2024
-4.17x
P/E 2025 -33.5x
Enterprise Value 18TCr 12Cr 10Cr 9.37Cr 8.77Cr 16Cr 1.1TCr 17Cr 112.5Cr 44Cr 537.96Cr 43Cr 43Cr 1.87TCr EV / Sales 2024
1.31x
EV / Sales 2025 8.97x
Free-Float
82.74%
Yield 2024 *
-
Yield 2025 -
13/04 Genome & Company announced that it has received KRW 6.99999414 billion in funding CI
03/04 Genome & Company announced that it expects to receive KRW 6.99999414 billion in funding CI
13/03 Genome & Company announced that it has received KRW 29.99998254 billion in funding from DongKoo Bio & Pharma Co., Ltd. CI
22/25/22 Genome & Company(KOSDAQ:A314130) dropped from S&P Global BMI Index CI
21/25/21 An undisclosed buyer agreed to acquire 40.12% stake in List Biotherapeutics, Inc. from Genome & Company for $19.1 million. CI
11/25/11 Genome & Company announced that it has received KRW 25.7890592 billion in funding CI
28/25/28 Genome & Company announced that it has received KRW 27.066097613 billion in funding from a group of investors CI
24/25/24 Genome & Company announced that it expects to receive KRW 27.066097613 billion in funding from a group of investors CI
24/25/24 Genome & Company announced that it expects to receive KRW 27.06426965 billion in funding CI
24/25/24 Genome & Company agreed to acquire an additional 28.64% stake in List Biotherapeutics, Inc. from a group of shareholders for KRW 27.07 billion. CI
19/24/19 Genome & Company announced that it has received KRW 4.5 billion in funding from Paratus New Normal CB Private Equity Fund Co., Ltd, Susung Asset Management Co., Ltd. CI
17/24/17 Genome & Company announced that it expects to receive KRW 4.5 billion in funding from Paratus New Normal CB Private Equity Fund Co., Ltd, Susung Asset Management Co., Ltd. CI
24/24/24 Genome & Company Announces Positive Topline Results from Phase 2 Clinical Trial of Combination of GEN-001 and Bavencio®? for the Treatment of Gastric Cancer Poster Presented at ASCO GI CI
1 day-8.75%
1 week-21.84%
Current month-29.25%
1 month-23.36%
3 months-51.67%
6 months-36.14%
Current year-37.06%
1 week 4,310
Extreme 4310
5,950
1 month 4,310
Extreme 4310
6,320
Current year 4,310
Extreme 4310
10,180
1 year 2,440
Extreme 2440
10,180
3 years 2,170
Extreme 2170
10,180
5 years 2,170
Extreme 2170
28,800
10 years 2,170
Extreme 2170
47,500
Manager TitleAgeSince
Chief Executive Officer 53 24/09/2015
Chief Executive Officer 55 24/09/2015
Director TitleAgeSince
Director/Board Member 55 24/09/2015
Director/Board Member 62 -
Director/Board Member 53 24/09/2015
Date Insider Type Main position Quantity % Market Cap.
09/25/09Free 20,000 0.0643%
09/25/09Don

Chief Executive Officer

1,00,000 0.3217%
09/25/09Free 10,000 0.0322%
Change 5-day change 1-year change 3-year change Capi.($)
-8.75%-21.84%+60.97%-51.35% 14Cr
+2.96%+4.08%-8.03%-2.24% 4.32TCr
+2.23%+8.26%+323.35%+564.22% 3.53TCr
+1.59%+4.63%+7.23%+54.02% 3.02TCr
+2.07%-4.40%+10.38%-19.99% 2.8TCr
-4.75%-8.29%+3.90%+13.88% 2.41TCr
+4.64%+3.20% - - 1.42TCr
+3.91%+2.57%+53.41%+111.95% 1.3TCr
+2.77%+2.93%+9.65%+11.90% 1.27TCr
+0.13%+3.97%+101.73%+91.70% 1.25TCr
Average +0.65%-2.97%+62.51%+86.01% 2.13TCr
Weighted average by Cap. +1.57%-0.74%+69.06%+120.24%

Financials

2024 2025
Net sales 2.77TCr 1.81Cr 1.59Cr 1.46Cr 1.37Cr 2.57Cr 171.43Cr 2.61Cr 18Cr 6.81Cr 84Cr 6.79Cr 6.65Cr 292.34Cr 2.46TCr 1.6Cr 1.41Cr 1.3Cr 1.22Cr 2.28Cr 151.92Cr 2.32Cr 16Cr 6.03Cr 75Cr 6.02Cr 5.89Cr 259.07Cr
Net income -2.01TCr -1.31Cr -1.15Cr -1.06Cr -99.41L -1.86Cr -124.27Cr -1.89Cr -13Cr -4.94Cr -61Cr -4.92Cr -4.82Cr -211.92Cr -642.81Cr -41.93L -36.83L -33.94L -31.77L -59.53L -40Cr -60.53L -4.08Cr -1.58Cr -19Cr -1.57Cr -1.54Cr -68Cr
Net Debt -4.89TCr -3.19Cr -2.8Cr -2.58Cr -2.42Cr -4.53Cr -302.18Cr -4.61Cr -31Cr -12Cr -148.27Cr -12Cr -12Cr -515.32Cr -1.79TCr -1.17Cr -1.02Cr -94.31L -88.29L -1.65Cr -110.37Cr -1.68Cr -11Cr -4.38Cr -54Cr -4.37Cr -4.28Cr -188.21Cr
Logo Genome & Company
Genome&Company Inc is a Korea-based company primarily engaged in the business of new drug development. The Company operates its business through three segments. The New Drug Development segment primarily develops anticancer drugs and microbiome medicines. The Contract Development and Manufacturing Organization (CDMO) segment primarily provides microbiome therapeutic contract development and manufacturing organization services. The Consumer segment primarily engages in the microbiome cosmetics and health functional food business.
Employees
-
Date Price Change Volume
23/26/23 4,330.00 -8.75% 6,10,088
22/26/22 ₩4,745.00 -2.87% 4,26,323
19/26/19 ₩4,885.00 -7.31% 4,43,363
18/26/18 ₩5,270.00 -5.89% 5,81,842
17/26/17 ₩5,600.00 +1.08% 11,24,045
  1. Stock Market
  2. Stocks
  3. A314130 Stock
-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!